Selected article for: "immune response and marked increase"
Author: Bouadma, Lila; Wiedemann, Aurélie; Patrier, Juliette; Surénaud, Mathieu; Wicky, Paul-Henri; Foucat, Emile; Diehl, Jean-Luc; Hejblum, Boris P.; Sinnah, Fabrice; de Montmollin, Etienne; Lacabaratz, Christine; Thiébaut, Rodolphe; Timsit, J. F.; Lévy, Yves
Title: Immune Alterations in a Patient with SARS-CoV-2-Related Acute Respiratory Distress Syndrome
  • Cord-id: smnu122h
  • Document date: 2020_8_22
    • ID: smnu122h
    Snippet: We report a longitudinal analysis of the immune response associated with a fatal case of COVID-19 in Europe. This patient exhibited a rapid evolution towards multiorgan failure. SARS-CoV-2 was detected in multiple nasopharyngeal, blood, and pleural samples, despite antiviral and immunomodulator treatment. Clinical evolution in the blood was marked by an increase (2–3-fold) in differentiated effector T cells expressing exhaustion (PD-1) and senescence (CD57) markers, an expansion of antibody-se
    Document: We report a longitudinal analysis of the immune response associated with a fatal case of COVID-19 in Europe. This patient exhibited a rapid evolution towards multiorgan failure. SARS-CoV-2 was detected in multiple nasopharyngeal, blood, and pleural samples, despite antiviral and immunomodulator treatment. Clinical evolution in the blood was marked by an increase (2–3-fold) in differentiated effector T cells expressing exhaustion (PD-1) and senescence (CD57) markers, an expansion of antibody-secreting cells, a 15-fold increase in γδ T cell and proliferating NK-cell populations, and the total disappearance of monocytes, suggesting lung trafficking. In the serum, waves of a pro-inflammatory cytokine storm, Th1 and Th2 activation, and markers of T cell exhaustion, apoptosis, cell cytotoxicity, and endothelial activation were observed until the fatal outcome. This case underscores the need for well-designed studies to investigate complementary approaches to control viral replication, the source of the hyperinflammatory status, and immunomodulation to target the pathophysiological response. The investigation was conducted as part of an overall French clinical cohort assessing patients with COVID-19 and registered in clinicaltrials.gov under the following number: NCT04262921. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1007/s10875-020-00839-x) contains supplementary material, which is available to authorized users.

    Search related documents:
    Co phrase search for related documents
    • acute ards respiratory distress syndrome and adaptive innate immunity: 1, 2, 3, 4, 5
    • acute ards respiratory distress syndrome and liver failure: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15
    • acute ards respiratory distress syndrome and longitudinal analysis: 1, 2
    • acute ards respiratory distress syndrome and lopinavir ritonavir: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35
    • acute ards respiratory distress syndrome and low frequency: 1
    • acute ards respiratory distress syndrome and low lymphocyte count: 1, 2
    • acute ards respiratory distress syndrome and lung describe: 1, 2, 3, 4, 5
    • acute ards respiratory distress syndrome and lung injury: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75
    • acute ards respiratory distress syndrome and lung macrophage: 1, 2, 3, 4, 5, 6, 7, 8
    • acute ards respiratory distress syndrome and lung traffic: 1
    • acute ards respiratory distress syndrome and lymphocyte count: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37
    • acute fever and adaptive innate: 1
    • acute fever and liver failure: 1
    • acute fever and longitudinal analysis: 1
    • acute fever and lopinavir ritonavir: 1, 2, 3, 4
    • acute fever and lung describe: 1
    • acute fever and lung injury: 1, 2, 3, 4
    • acute fever and lymphocyte count: 1
    • acute fever and macaque model: 1, 2